Internal link ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor September 23, 2026 at 12:00 PM UTC
Internal link ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026 September 09, 2026 at 12:00 PM UTC
Internal link ProQR to Participate in Upcoming Investor Conferences in September 2026 September 02, 2026 at 12:00 PM UTC
Internal link ProQR Announces Second Quarter 2026 Operating and Financial Results August 13, 2026 at 11:00 AM UTC
Internal link ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement June 25, 2026 at 10:35 AM UTC
Internal link ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform June 25, 2026 at 10:25 AM UTC
Internal link ProQR Announces First Quarter 2026 Operating and Financial Results May 12, 2026 at 11:00 AM UTC
Internal link ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform May 11, 2026 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 May 04, 2026 at 12:00 PM UTC
Internal link ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors April 30, 2026 at 12:00 PM UTC
Internal link ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event April 08, 2026 at 08:00 PM UTC
Internal link ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board April 08, 2026 at 12:00 PM UTC
Internal link ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 March 25, 2026 at 12:00 PM UTC
Internal link ProQR Announces Year End 2025 Operating and Financial Results March 12, 2026 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference March 03, 2026 at 09:30 PM UTC
Internal link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook January 08, 2026 at 01:00 PM UTC
Internal link ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration December 11, 2024 at 12:00 PM UTC
Internal link ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist December 10, 2024 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 December 05, 2024 at 01:00 PM UTC
Internal link ProQR Announces Third Quarter 2024 Operating and Financial Results November 07, 2024 at 12:00 PM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement October 25, 2024 at 08:45 PM UTC
Internal link ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement October 23, 2024 at 02:15 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares October 22, 2024 at 08:01 PM UTC
Internal link ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society October 07, 2024 at 12:00 PM UTC